Expanding benefits from cardiac resynchronization therapy to exercise-induced left bundle branch block in advanced

Fernando L Scolari1, Anderson D Silveira1,2, Willian R Menegazzo1

  • 1Cardiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rua Ramiro Barcelos, 2350, room 2060, Porto Alegre, RS, 90035-903, Brazil.

ESC Heart Failure
|January 11, 2020
PubMed

Insights

Cardiac resynchronization therapy (CRT) may benefit patients with heart failure and reduced ejection fraction experiencing exercise-induced left bundle branch block. This intervention improved functional capacity and exercise parameters in a patient case study.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Heart Failure Management

Background:

  • Cardiac resynchronization therapy (CRT) is indicated for heart failure with reduced ejection fraction (HFrEF) and left bundle branch block (LBBB).
  • Exercise-induced LBBB is not a current standard indication for CRT.
  • Patients with HFrEF often present with significant functional impairment.

Observation:

  • A 57-year-old woman with idiopathic dilated cardiomyopathy (ejection fraction 23%) and NYHA Class IV symptoms experienced recurrent hospitalizations.
  • During a cardiopulmonary exercise test for heart transplant evaluation, a new onset of intermittent left bundle branch block was detected.
  • This patient had no LBBB at rest but demonstrated electromechanical dyssynchrony during exertion.

Findings:

  • CRT was implanted, achieving a 97% resynchronization rate.
  • Following CRT implantation, the patient showed significant improvements in both clinical and prognostic exercise parameters at 12-month follow-up.
  • The case demonstrates that CRT can be effective in improving functional capacity in selected HFrEF patients with exercise-induced LBBB.

Implications:

  • Cardiopulmonary exercise testing may reveal subclinical electromechanical dyssynchrony in HFrEF patients without resting LBBB.
  • Identifying exercise-induced LBBB could expand the criteria for CRT candidacy.
  • CRT may offer a viable therapeutic option for improving exercise tolerance and quality of life in this patient population.

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
207
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
702
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
260
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
846
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
388
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
311